Richard Kefford

Skolkovo Institute of Science and Technology — Russia

Biochemistry, Genetics and Molecular Biology · Life Sciences

125h-index102.4kcitations613works0.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(242), Cutaneous Melanoma Detection and Management(165), Cancer Immunotherapy and Biomarkers(111), CAR-T cell therapy research(94), Cancer Genomics and Diagnostics(93)

Publications542 total

Data from Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

2023Open Access

Supplemental table S2 from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

2023Open Access

Data from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

2023Open Access

Supplemental table S3 from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

2023Open Access

Supplemental table S2 from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

2023Open Access

Figure S2 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

2023Open Access

Supplementary Table 2 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

2023Open Access

Data from Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

2023Open Access

Suppementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

2023Open Access

Data from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

2023Open Access

Table S1 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

2023Open Access

Supplementary Table 1 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

2023Open Access

Data from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

2023Open Access

Figure Legends from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

2023Open Access

Supplementary Data - Tracked from Correlation of <i>BRAF</i> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

2023Open Access

Supplementary Table 1 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

2023Open Access

Table S2 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

2023Open Access

Supplementary Table 3 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

2023Open Access

Supplementary Figure 1 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

2023Open Access

Supplemental figure 1 from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

2023Open Access

page 1 of 28Next →

Frequent Co-authors

Georgina V. Long(28), Richard A. Scolyer(17), Antoni Ribas(16), Omid Hamid(14), John F. Thompson(13), Alexander M. Menzies(13), Caroline Robert(12), Jeffrey S. Weber(12), Adil Daud(11), Peter Hersey(11), F. Stephen Hodi(10), Graham J. Mann(10), Matteo S. Carlino(10), Wen-Jen Hwu(8), Jedd D. Wolchok(8), Richard W. Joseph(8), Roxana Dronca(8), Amita Patnaik(8), Anthony M. Joshua(8), Scot Ebbinghaus(8)